Key statistics
On Tuesday, Akari Therapeutics PLC (CLA:FRA) closed at 2.68, -31.28% below its 52-week high of 3.90, set on Jul 30, 2024.
52-week range
Open | 2.68 |
---|---|
High | 2.68 |
Low | 2.68 |
Bid | -- |
Offer | -- |
Previous close | 2.68 |
Average volume | 0.00 |
---|---|
Shares outstanding | 607.23k |
Free float | 485.78k |
P/E (TTM) | -- |
Market cap | 36.86m USD |
EPS (TTM) | -2.98 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 07:18 BST.
More ▼
Announcements
- Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
- Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
- Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
More ▼